Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06566170 · ClinicalTrials.gov registry record
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
A clinical trial of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- 6,250
- Enrollment target
- 1
- Study location
NCT06566170 is a study of Alzheimer Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 6,250 participants, above the 2,730-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (129% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06566170, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- 6,250 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
Conditions Studied
Interventions
- DRUG Usual Care
- DRUG Donanemab
Study Locations (1)
Alabama
- Rehabilitation & Neurological Services - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,250 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2033-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06566170
The ClinicalTrials.gov registry entry for NCT06566170 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,730-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (129% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT06566170 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06566170 about?
NCT06566170 is a clinical study titled "A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease". The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the...
What is the current status of trial NCT06566170?
This trial is currently recruiting. The enrollment target is 6,250 participants. The study started on 2024-10-07. Estimated completion is 2033-02.
What conditions does trial NCT06566170 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06566170?
The interventions under investigation include: Usual Care (DRUG), Donanemab (DRUG).
Who is sponsoring clinical trial NCT06566170?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06566170 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.